How much cash does Upexi generate?

Upexi (UPXI) generated -$21.5M in operating cash flow over the trailing twelve months.

What is Upexi's free cash flow?

After $233.8K of capital expenditures, Upexi's free cash flow was -$21.8M over the trailing twelve months, down 158.3% year over year.

Where does Upexi's cash flow data come from?

Every line is extracted from Upexi's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Upexi UPXI Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q3 '26	TTM Q2 '26	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25
Depreciation and amortization	$457.35K-74.0%	$567.58K-76.3%	$653.76K-78.2%	$757.76K-79.4%	$1.76M-36.2%
Stock-based compensation	$19.46M+2,062%	$15.99M+2,604%	$7.72M+768%	$2.11M+80.1%	$899.84K-40.1%
Amortization of debt issuance costs	$2.72M+6,566%	$27.89K-53.9%	$27.89K-68.8%	$30.46K-73.7%	$40.81K—
Impairment charges	——	——	——	$0-100%	$1.97M-71.2%
Gain (loss) on sale of assets	——	——	——	——	——
Provision for credit losses	——	——	——	——	——
Change in accounts receivable	——	——	——	——	——
Change in inventories	-$860.35K—	——	——	——	——
Change in accounts payable	$5.52M—	$5.81M—	$5.56M—	$2.87M—	——
Change in other assets	——	——	——	——	——
Change in deferred revenue	——	——	-$126.67K-622%	-$222.1K-319%	-$87.61K-291%
Loss on extinguishment of debt	——	——	——	——	——
Change in operating lease liabilities	——	——	——	——	——
Net cash from operating activities	-$21.52M—	-$17.53M—	-$16.23M—	-$8.42M—	——
Capital expenditures	$233.76K-50.0%	$252.63K-59.2%	$235.18K-70.8%	$387.76K-58.4%	$467.51K-64.6%
Proceeds from sale of businesses	——	——	——	——	——
Net cash from investing activities	——	——	——	——	——
Proceeds from issuance of debt	——	——	——	——	——
Repayments of debt	——	——	——	——	——
Proceeds from issuance of common stock	$160.02M—	$152.56M—	$142.56M—	$92.56M—	——
Payment of debt issuance costs	——	——	——	——	——
Proceeds from issuance of preferred stock	——	——	——	$325K—	$243.75K—
Net cash from financing activities	——	——	——	——	——
Net increase (decrease) in cash	$3.25M—	$1.21M—	$446.83K—	$2.31M—	——
Interest paid	$6.31M—	$3.01M—	$2.67M—	$805.88K—	——
Income taxes paid	$0—	$0—	$0—	$0—	$0—
Amortization expense related to capitalized debt issuance costs	$2.72M+6,566%	$27.89K-53.9%	$27.89K-68.8%	$30.46K-73.7%	$40.81K—
Non-cash interest expense	——	——	——	——	——
Unrealized loss on digital assets	——	——	——	——	——
Gain On The Sale Of Vitamedica And Income From Discontinued Operations	——	——	——	$0-100%	$487.13K-66.7%
Deferred revenue	——	——	-$126.67K-622%	-$222.1K-319%	-$87.61K-291%
Operating lease liabilities	——	——	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Inventory write-downs	——	——	——	——	——
Accounts Receivable, Credit Loss Expense (Reversal)	——	——	——	——	——
Impairment of long-lived assets	——	——	——	$0-100%	$84.11K-66.7%
Payment for Acquisition, Crypto Asset	——	——	——	——	——
Proceeds From Sale Of Buildings	——	——	——	——	——
Proceeds from sale of assets	——	——	——	——	——
Proceeds From The Sale Of E Core	——	——	——	——	——
Proceeds From The Sale Of Vitamedica Inc	——	——	——	——	——
Payments Of Debt Issuance Costs	——	——	——	——	——
Payments Of Stock Issuance Costs	——	——	——	——	——
Proceeds From Related Party Debt	——	——	——	$75K—	$156.25K—
Proceeds from issuance of commercial paper and other short-term borrowings	——	——	——	——	——
Proceeds From Warrant Exercises	——	——	$257.89K—	$250K—	$0—
Repayments Of Notes Payable	——	——	——	——	——
Repayments Of Related Party Debt	$75K—	——	——	——	——
Amortization Of Consideration Discount	——	——	——	$0-100%	$570.38K-69.5%
Crypto Asset Realized Loss Operating	——	——	——	——	——
Deferred Tax Asset Increase Decrease	——	——	——	$0-100%	$86.2K—
Increase Decrease In Operating Lease Liability	——	——	——	——	——
Increasedecreaseinloss On Sale Of Assets Related To Relocation Of Facility	——	——	——	$0+100%	-$142.3K—
Issuance Of Convertible Debt For Digital Assets Acquired	——	——	——	——	——
Issuance Of Short Term Debt For Digital Asssets Acquired	——	——	——	——	——
Non Cash Proceeds In The Sale Of Vitamedica	——	——	——	$0-100%	$475K—
Reduction Of Acquisition Payable	——	——	——	$152.5K—	$114.38K—
Income Taxes Paid, Net	$0—	$0—	$0—	$0—	$0—
Free cash flow	-$21.76M—	-$17.78M—	-$16.46M—	-$8.81M—	——
Free cash flow	-$21.76M—	-$17.78M—	-$16.46M—	-$8.81M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Upexi.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Upexi generate?: Upexi (UPXI) generated -$21.5M in operating cash flow over the trailing twelve months.
What is Upexi's free cash flow?: After $233.8K of capital expenditures, Upexi's free cash flow was -$21.8M over the trailing twelve months, down 158.3% year over year.
Where does Upexi's cash flow data come from?: Every line is extracted from Upexi's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.